Literature DB >> 24129368

CD8 T-cell activation is associated with lipodystrophy and visceral fat accumulation in antiretroviral therapy-treated virologically suppressed HIV-infected patients.

Giovanni Guaraldi1, Kety Luzi, Giusi Maria Bellistrì, Stefano Zona, Ana Rita Domingues da Silva, Francesca Bai, Elisa Garlassi, Giulia Marchetti, Jacqueline Capeau, Antonella d'Arminio Monforte.   

Abstract

OBJECTIVE: HIV-infected patients receiving antiretroviral treatment frequently accumulate fat at the abdominal level. It is unknown whether T-cell activation and immune phenotypes are associated with fat accumulation. Thus, the aim of the study was to search for an association between the presence of clinical lipodystrophy (LD), visceral and subcutaneous abdominal adipose tissue amount (VAT and SAT), and peripheral T-cell immune phenotypes.
DESIGN: Cross-sectional study including 87 HIV-infected antiretroviral therapy-treated virologically suppressed and immune-reconstituted patients.
METHODS: The patients were evaluated for clinical LD, VAT, SAT, homeostasis model of insulin resistance, and coronary artery calcium score (>10). T-cell activation (CD8/CD38), differentiation (CD4/CD8/CCR7/CD45RA), and expression/activation of the interleukin-7 (IL-7)/IL-7R system (CD4/CD8/CD127, IL-7, and CD4/CD8/pStat-5) were assessed by cytometry.
RESULTS: In multivariable analyses, CD8 T-cell activation (CD38) was associated with lipoatrophy and central fat accumulation (respectively, β = 5.63, P = 0.005, and β = 4.19, P = 0.020). This was also the case for IL-7R expressing CD8⁺ T cells (CD127⁺) for lipoatrophy β = 12.8, P = 0.003, and for central fat accumulation β = 9.45, P = 0.016. CD8⁺ T-cell activation was also associated with VAT/total adipose tissue (β = 0.01, P = 0.002) and SAT/VAT ratios (β = -0.014, P = 0.015). As expected, VAT/total adipose tissue was an independent risk factor for homeostasis model of insulin resistance (r = 0.364, P = 0.028) and cardiovascular risk (coronary artery calcium, r = 0.406, P = 0.002).
CONCLUSIONS: CD8⁺ T-cell activation was associated with LD and the relative amount of VAT in antiretroviral therapy-controlled, virologically suppressed, HIV-infected patients. We propose that CD8 activation may be involved in the accumulation of central fat frequently observed in these patients, with resulting increased cardiometabolic risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129368     DOI: 10.1097/QAI.0000000000000001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  12 in total

Review 1.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

2.  Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.

Authors:  Vanessa El Kamari; Carlee Moser; Corrilynn O Hileman; Judith S Currier; Todd T Brown; Liz Johnston; Peter W Hunt; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

Review 3.  The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.

Authors:  Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

Review 4.  HIV-1-Associated Atherosclerosis: Unraveling the Missing Link.

Authors:  Alison Kearns; Jennifer Gordon; Tricia H Burdo; Xuebin Qin
Journal:  J Am Coll Cardiol       Date:  2017-06-27       Impact factor: 24.094

5.  Collecting lymphatic vessel permeability facilitates adipose tissue inflammation and distribution of antigen to lymph node-homing adipose tissue dendritic cells.

Authors:  Emma L Kuan; Stoyan Ivanov; Eric A Bridenbaugh; Gabriel Victora; Wei Wang; Ed W Childs; Andrew M Platt; Claudia V Jakubzick; Robert J Mason; Anatoliy A Gashev; Michel Nussenzweig; Melody A Swartz; Michael L Dustin; David C Zawieja; Gwendalyn J Randolph
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

6.  CD4/CD8 Ratio Predicts Peripheral Fat in HIV-Infected Population.

Authors:  Tanawan Riangwiwat; Lindsay B Kohorn; Dominic C Chow; Scott A Souza; Lishomwa C Ndhlovu; Jennifer W H Wong; Louie Mar Gangcuangco; Cecilia M Shikuma
Journal:  J Acquir Immune Defic Syndr       Date:  2016-05-01       Impact factor: 3.731

Review 7.  Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection.

Authors:  Jordan E Lake; Takara L Stanley; Caroline M Apovian; Shalendar Bhasin; Todd T Brown; Jaqueline Capeau; Judith S Currier; Michael P Dube; Julian Falutz; Steven K Grinspoon; Giovanni Guaraldi; Esteban Martinez; Grace A McComsey; Fred R Sattler; Kristine M Erlandson
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

8.  Abdominal fat depots, insulin resistance, and incident diabetes mellitus in women with and without HIV infection.

Authors:  Marshall J Glesby; David B Hanna; Donald R Hoover; Qiuhu Shi; Michael T Yin; Phyllis C Tien; Mardge Cohen; Kathryn Anastos; Anjali Sharma
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.632

9.  Self-reported body fat change in HIV-infected men is a marker of decline in physical health-related quality of life with aging, independent of co-morbidity.

Authors:  Kristine M Erlandson; Sandra M Reynolds; Christopher Cox; Frank J Palella; Mallory D Witt; Lawrence A Kingsley; Todd T Brown; Michael Plankey
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 10.  HIV-associated lipodystrophy: a review from a Brazilian perspective.

Authors:  Marcelle D Alves; Carlos Brites; Eduardo Sprinz
Journal:  Ther Clin Risk Manag       Date:  2014-07-17       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.